AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33217050
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 1000 mg/day, n = 26
Trial: 32622784
Drug: GLE 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLE 400 mg + PIB 120 mg
Trial: 32622784
Drug: GLE 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLE 600 mg + PIB 240 mg
Trial: 32299515
Drug: Best practices
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best practices implementation in pancreatic cancer care (including (neo)adjuvant and palliative chemotherapy, pancreatic enzyme replacement therapy, and metal biliary stents)
Trial: 32227368
Drug: Fluoxetine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine with cognitive behavioral therapy for 1 year
Trial: 32227368
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with cognitive behavioral therapy for 1 year
Trial: 35690500
Drug: ASP3772 (1-,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3772 (1-, 2-, or 5-µg dose per polysaccharide)
Trial: 35690500
Drug: PCV13 (13-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 (13-valent conjugate vaccine)
Trial: 34541683
Drug: Enamel matrix
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enamel matrix derivative (EMD) 0.3 ml
Trial: 33732434
Drug: Intranasal esketamine
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intranasal esketamine (56mg) administered twice a week for four consecutive weeks
Trial: 32858573
Drug: Nadroparin calcium-warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin calcium-warfarin sequential (NWS) therapy (1-month nadroparin calcium by subcutaneous injection followed by 5-month warfarin by oral administration)
Trial: 32858573
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anticoagulation therapy)
Trial: 32858573
Drug: NWS anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NWS anticoagulation therapy
Trial: 32858573
Drug: NWS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NWS therapy group
Trial: 35090535
Drug: IV lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lidocaine infusion (2% lidocaine) for 6–12 hours starting at the beginning of surgery
Trial: 35090535
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion for 6–12 hours starting at the beginning of surgery
Trial: 34258469
Drug: TOTAL intervention
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOTAL intervention (18-min video highlighting obesity health risks and treatment outcomes)
Trial: 33090921
Drug: PRC-063 (methylphenidate),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRC-063 (methylphenidate), 25 mg/day titrated to maximum 85 mg/day
Trial: 35412603
Drug: Japanese Encephalitis
RxNorm normalized name: Japanese Encephalitis IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese Encephalitis (JE) vaccine
Trial: 35488487
Drug: Brand metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brand metoprolol ER tablets
Trial: 35488487
Drug: Drug 1
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1 (generic metoprolol ER)
Trial: 35488487
Drug: Drug 2
RxNorm normalized name: Hartig Drug 29G 1/2 inch Unifine Pentips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 2 (generic metoprolol ER)
Trial: 35595658
Drug: Durvalumab in
RxNorm normalized name: durvalumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab in addition to anthracycline taxane-based neoadjuvant therapy
Trial: 34410254
Drug: Proprioception training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proprioception training twice a week for eight weeks along with diabetes awareness lectures once a week
Trial: 32207209
Drug: BFR+ (Biofermin-R)
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFR+ (Biofermin-R) with VPZ-based therapy
Trial: 33407264
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin bilateral medial rectus injections
Trial: 34821127
Drug: Tablet Atorvastatin
RxNorm normalized name: atorvastatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Atorvastatin for 60 days along with lifestyle modification
Trial: 37610062
Drug: Imeglimin monotherapy
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin monotherapy at 1,500 mg
Trial: 37610062
Drug: Imeglimin monotherapy
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin monotherapy at 2,000 mg
Trial: 37610062
Drug: Imeglimin adjunctive
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin adjunctive therapy at 1,000 mg
Trial: 37610062
Drug: Imeglimin adjunctive
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin adjunctive therapy at 1,500 mg
Trial: 37610062
Drug: Imeglimin (monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imeglimin (monotherapy and adjunctive therapy)
Trial: 32900519
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg trans-resveratrol twice-daily for 12 months
Trial: 36054038
Drug: Edaravone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone treatment after placebo
Trial: 34773302
Drug: Combined photodynamic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined photodynamic therapy (combPDT)
Trial: 34152936
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (cPDT)
Trial: 35471471
Drug: Low-dose Lingguizhugan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Lingguizhugan Decoction (LGZG)
Trial: 35471471
Drug: Standard-dose Lingguizhugan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose Lingguizhugan Decoction (LGZG)
Trial: 34939395
Drug: Shumian capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shumian capsule
Trial: 34939395
Drug: Shumian capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shumian capsule simulator (control)
Trial: 32212275
Drug: TransCon PTH
RxNorm normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon PTH (3.5 to 124 μg PTH(1‐34) for SAD; 3.5 to 24 μg PTH(1‐34)/day for MAD)
Trial: 32885276
Drug: Midodrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (20 mg orally every 8 hours)
Trial: 32885276
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral every 8 hours)
Trial: 32885276
Drug: Midodrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (20 mg)
Trial: 34546088
Drug: Twice-daily intensified
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily intensified rehabilitation training with HBO (Study Group B)
Trial: 34546088
Drug: Twice-daily intensified
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily intensified rehabilitation training without HBO (Study Group C)
Trial: 33709484
Drug: Forgiveness Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forgiveness Therapy for 24 weeks
Trial: 33709484
Drug: Alternative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative treatment for 24 weeks followed by Forgiveness Therapy
Trial: 32056414
Drug: G-aenial Universal
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-aenial Universal Flo with self-etch
Trial: 32056414
Drug: G-aenial Universal
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-aenial Universal Flo with etch&rinse
Trial: 35854250
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy adapted for GAD (CBT-A)
Trial: 34403326
Drug: Isoniazid 15
RxNorm normalized name: isoniazid 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoniazid 15 mg/kg
Trial: 34543941
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + Denosumab
Trial: 35037373
Drug: One avocado
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One avocado daily for 8 weeks
Trial: 34080265
Drug: Cosmos caudatus
RxNorm normalized name: Amaranthus caudatus seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cosmos caudatus (CC) supplementation (two 500 mg capsules daily for 12 weeks)
Trial: 33847614
Drug: Shenhuang plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenhuang plaster application on shenque point (CV8) plus chemotherapy treatment
Trial: 34183087
Drug: Tablet-based intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet-based intervention (TBI)
Trial: 32588401
Drug: Solriamfetol 150
RxNorm normalized name: solriamfetol 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 150 mg
Trial: 32588401
Drug: Solriamfetol 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solriamfetol 300 mg
Trial: 34308735
Drug: Zi Gui
RxNorm normalized name: Bai jie zi
DrugBank: White mustard seed (DB15606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zi Gui Nv Zhen® capsules (ZGNZC)
Trial: 33516752
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (IPE) 2 grams by mouth twice daily with meals
Trial: 32636109
Drug: 10‐mg dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg dexamethasone (2 doses)
Trial: 32636109
Drug: 10‐mg dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg dexamethasone (3 doses)
Trial: 37903861
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg/day
Trial: 36045306
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping with conventional physical therapy (CPT)
Trial: 36045306
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (CPT) only
Trial: 32589977
Drug: Selinexor 60
RxNorm normalized name: selinexor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 60 mg orally on days 1 and 3 weekly until disease progression or unacceptable toxicity
Trial: 33909232
Drug: Selinexor 60
RxNorm normalized name: selinexor 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor 60 mg
Trial: 32456804
Drug: ASP3652 30-900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3652 30-900 mg single dose
Trial: 32456804
Drug: ASP3652 100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP3652 100-300 mg BID multiple doses
Trial: 34548116
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (stationary cycling) performed daily for 1 week
Trial: 34548116
Drug: Non-aerobic exercise
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aerobic exercise (stretching and calisthenics) performed daily for 1 week
Trial: 34763506
Drug: Dialectical behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialectical behavior therapy intervention for 4 weeks
Trial: 37944025
Drug: Biological mesh
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological mesh
Trial: 35966250
Drug: Dapagliflozin combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin combined with metoprolol sustained-release tablets (Group A)
Trial: 32197277
Drug: Inclisiran (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (300 mg subcutaneous injections on days 1, 90, 270, and 450)
Trial: 32197277
Drug: Inclisiran (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclisiran (300 mg)
Trial: 33066869
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg/day)
Trial: 32773484
Drug: Universal Testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal Testing and Treatment (UTT)
Trial: 33822441
Drug: Active placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active placebo (0.04 g/kg)
Trial: 33430604
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus eptifibatide
Trial: 34004189
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin A 5000 IU 3 times weekly for 4 weeks
Trial: 34411060
Drug: Droperidol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (20 µg/kg)
Trial: 32108686
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 150 µg
Trial: 35085017
Drug: Equine-Assisted Activities
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equine-Assisted Activities and Therapies (EAAT) program conducted for 40 min twice a week for 16 weeks (32 lessons)
Trial: 36030106
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg)
Trial: 32025814
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg/d) during immobilization and retraining
Trial: 32830368
Drug: Abstinence-optimized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence-optimized treatment (A-OT, n = 276)
Trial: 35712433
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement
Trial: 35712433
Drug: Delayed implant
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed implant placement
Trial: 32666172
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered isotretinoin
Trial: 32666172
Drug: Combined intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravitreal prophylactic approach of 5-fluorouracil and low molecular weight heparin
Trial: 33279182
Drug: Checkpoint inhibitors
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Checkpoint inhibitors
Trial: 36846138
Drug: Low-dose atorvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose atorvastatin
Trial: 35442486
Drug: Epoetin-alpha plus
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alpha plus insulin therapy (Control)
Trial: 33345336
Drug: Methadone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone therapy
Trial: 35010932
Drug: Moringa oleifera
RxNorm normalized name: Moringa Oleifera
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moringa oleifera (MO) supplementation (2400 mg/day, 6 capsules daily)
Trial: 32504219
Drug: Second-line treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line treatment
Trial: 35060229
Drug: Topical triple
RxNorm normalized name: Triple Paste Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triple combination (TXA 5% + OXZ 1.5% + BMT 0.33%) applied on the right side of the face
Trial: 35060229
Drug: Topical lipocream
RxNorm normalized name: Hydrocortisone Butyrate 0.1% Topical Lipocream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lipocream (placebo) applied on the left side of the face
Trial: 32170033
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin 20 mg/kg every 24 hours for 3 days
Trial: 32270176
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (reduced from weekly to every other week)
Trial: 32270176
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (increased from every other week to weekly)
Trial: 32441171
Drug: Rehydration for
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehydration for 60 minutes in 0.9% saline solution
Trial: 32100373
Drug: Short day
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short day (SD; 8 L:16 D)
Trial: 32100373
Drug: Control (CTR;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CTR; 12.5 L:11.5 D)
Trial: 34724566
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy
Trial: 33568510
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of DNA GTU-MultiHIV B at week 0, 4, and 12, followed by 2 doses of LIPO-5 vaccine at week 20 and 24
Trial: 33516464
Drug: Dietary supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplementation of Bupleurum falcatum L saikosaponins (80 mg/kg of diet)
Trial: 33036662
Drug: Ginger-based herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger-based herbal tablets (Vomigone ®) at a dose of 1000 mg three times a day for seven days
Trial: 33036662
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for COVID-19 along with Vomigone-like placebo tablets
Trial: 33036662
Drug: Ginger-based herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger-based herbal tablets (Vomigone ®)
Trial: 35984871
Drug: Ashwagandha (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha (700 mg daily, full spectrum extract of ASH root)
Trial: 35213904
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment (rectal ibuprofen or intravenous acetaminophen)
Trial: 36034411
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment
Trial: 32677051
Drug: Ketamine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (single intravenous dose)
Trial: 38914481
Drug: High-intensity focused
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity focused ultrasound (HIFU) treatment
Trial: 36267766
Drug: Kai Hou
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kai Hou Jian (2.5 mL via transoral atomization twice daily for 1 week)
Trial: 36267766
Drug: Budesonide (1
RxNorm normalized name: budesonide (11.beta.,16.alpha.(S))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (1 mg nebulization twice daily for 1 week)
Trial: 35054027
Drug: ANI-guided remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANI-guided remifentanil administration
Trial: 32945735
Drug: Dried cranberry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried cranberry powder (500 mg)
Trial: 33895361
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Trial: 33895361
Drug: Add-on peginterferon-alpha2b
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add-on peginterferon-alpha2b (1.5 μg/kg/weekly) for 48 weeks
Trial: 33276811
Drug: Antiviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy alone (same scheme as in stage 1)
Trial: 36097674
Drug: Cabotegravir +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabotegravir + rilpivirine LA injections
Trial: 33340084
Drug: Fixed implant‐supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed implant‐supported prostheses (FP)
Trial: 33340084
Drug: Removable implant‐supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable implant‐supported prostheses (RP)
Trial: 32536023
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g 2’FL/LNnT
Trial: 32536023
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g 2’FL/LNnT